NASDAQ:AGRX - Agile Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.48 -0.03 (-5.88 %)
(As of 07/18/2018 08:00 AM ET)
Previous Close$0.51
Today's Range$0.47 - $0.53
52-Week Range$0.44 - $5.60
Volume599,300 shs
Average Volume288,893 shs
Market Capitalization$17.53 million
P/E Ratio-0.53
Dividend YieldN/A
Agile Therapeutics logoAgile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio2.35
Quick Ratio2.35


Trailing P/E Ratio-0.53
Forward P/E Ratio-0.73
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book0.45


EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-81.74%
Return on Assets-56.48%


Outstanding Shares34,250,000
Market Cap$17.53

The Truth About Cryptocurrencies

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) posted its quarterly earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. View Agile Therapeutics' Earnings History.

What price target have analysts set for AGRX?

6 brokerages have issued 12-month price objectives for Agile Therapeutics' shares. Their predictions range from $3.00 to $13.00. On average, they anticipate Agile Therapeutics' share price to reach $6.25 in the next twelve months. This suggests a possible upside of 1,202.1% from the stock's current price. View Analyst Ratings for Agile Therapeutics.

What is the consensus analysts' recommendation for Agile Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:
  • 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a decline in short interest in the month of June. As of June 29th, there was short interest totalling 248,838 shares, a decline of 59.2% from the June 15th total of 609,828 shares. Based on an average daily volume of 379,813 shares, the short-interest ratio is presently 0.7 days. Currently, 1.3% of the shares of the company are sold short. View Agile Therapeutics' Current Options Chain.

Who are some of Agile Therapeutics' key competitors?

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the folowing people:
  • Mr. Alfred F. Altomari, Chairman & CEO (Age 59)
  • Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 50)
  • Ms. Mary Coleman, Head of Investor Relations & Corp. Communications
  • Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)

Has Agile Therapeutics been receiving favorable news coverage?

Media stories about AGRX stock have trended positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.36 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 46.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include CAXTON CORP (2.00%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $0.48.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $17.53 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]

MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.